TrialNCT02143973Phase 2, phase 3Completed
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Study sponsor: Trevi Therapeutics
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2016-01Actual
Enrollment · participants167Actual
Source updated2025-05-21Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.